Glycolipid mimetics with selective anti or pro-inflammatory response

Patent number:

EP21382980, EP21382981

Andalucía.svg
No items found.

Novel glycolipid mimetics have been identified that are able to express anti inflammatory or adjuvant activity in a context dependent manner The compounds can be used for the treatment of immune diseases cursed with Th 1 /Th 2 imbalance or as vaccine adjuvants

Countries:
Spain
Regions:
Andalusia
Centers:
CSIC
Other entities:
Sectors:
Health
Subsectors:
Pharmaceuticals
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
Applications

Los compuestos selectivos han mostrado supresión de la inflamación inducida por α-GalCer o LPS in vitro e in vivo. Algunos compuestos fueron competentes para inducir una respuesta sesgada hacia Th1 y otros hacia Th2. Capacidad de suprimir la inflamación Th2 confirmada in vivo en un modelo de hiperreactividad de las vías respiratorias inducida por ovoalbúmina (OVA) en ratones. Capacidad adyuvante de algunos compuestos demostrada in vivo.

Comments

Other related patents

Health

PREVENTION AND/OR TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH DEMENTIA SYNDROMES

Countries
Spain
Know more
Health

Use of aloe oral for hair improvement

Countries
Spain
Know more
Other
Health

SYSTEM AND METHOD FOR SECURE OUTSOURCED ANNOTATION OF DATASETS

Countries
Spain
Know more
Get back to patents directory